Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

SALVOVAR will be a pragmatic open-label multicenter randomized phase III trial (ratio 1:1) comparing the efficacy of the salvage weekly dose-dense regimen with those of the continuation of the standard regimen.

Trial Details

NCT ID
NCT06476184
Phase
PHASE3
Sponsor
ARCAGY/ GINECO GROUP
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Carboplatin
  • Paclitaxel
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Avignon, France|43.94834,4.80892
  • Bayonne, France|43.49316,-1.473
  • Besançon, France|47.24878,6.01815
  • Bordeaux, France|44.84124,-0.58046

Key Eligibility Criteria

  • Histologically confirmed high-grade epithelial (serous, endometrioid, or carcinosarcoma with a ≥30% epithelial tumor component) ovarian, primary pe…
  • Adult patient aged ≥ 18 years old
  • Advanced stage III or IV disease
  • Treated with 3 to 4 neo-adjuvant cycles of standard 3-weekly carboplatin-paclitaxel regimen in first-line setting, and characterized by:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →